'Have to keep up this pace': As new Vir CEO, Marianne De Backer eyes expansion beyond infectious disease
On day two in the CEO seat at Vir Biotechnology, Marianne De Backer — a prolific, two-decade dealmaker in biopharma — said she’s ready to move fast like she did slinging deals at Bayer and Johnson & Johnson before that.
The Covid-19 and Ebola drugmaker, hoping to make major dents in influenza, hepatitis B and D with crucial Phase II data readouts later this year to determine that future, will also look beyond infectious diseases, De Backer told Endpoints News on Tuesday. They’re also looking to make RSV antibodies with the help of pandemic partner GSK, which opted to move forward on the respiratory virus last September as vaccines could soon come to market. An HIV prophylaxis asset is in early-stage testing as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
